In the agreement with CoreValve, Medtronic will pay $700 million plus additional payments contingent on the achievement of agreed upon milestones. Medtronic will acquire Ventor for $325 million.
CoreValve is the developer of a transcatheter, transfemoral aortic valve replacement product. Ventor is the developer of two cardiovascular technologies — a minimally invasive, surgical transapical technology and a next-generation percutaneous, transfemoral technology.
Read the Medtronic news release on the acquisition of CoreValve.
Read the Medtronic news release on the acquisition of Ventor Technologies.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.